Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing.
ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee health testing. Psychemedics was selected for its exceptional performance, industry leadership, and dedication to delivering reliable and accurate testing services.
“We are honored to be recognized as one of the Top 10 Employee Health Testing Services Providers,” said Brian Hullinger, Chief Executive Officer and President of Psychemedics Corporation. “This achievement is a testament to our unwavering commitment to providing high-quality, innovative solutions for drug testing.”
Psychemedics’ patented hair analysis technology offers a non-invasive and highly accurate method for detecting drug use over an extended period, providing employers with valuable insights into their employees’ health and well-being. With over 30 years of experience, Psychemedics has helped thousands of companies worldwide maintain safe and drug-free workplaces.
For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit https://www.psychemedics.com.
About Psychemedics
Psychemedics Corporation (NASDAQ: PMD) is a leading global provider of innovative hair testing for drugs of abuse. With over 30 years of experience, Psychemedics has pioneered the science of hair testing and provides clients with the most accurate and reliable hair drug test results in the industry. The company's patented technology is used by thousands of companies worldwide to screen applicants and employees for drug use, helping to create safer and more productive workplaces.
Investor Relations:
Phone: 978-206-8220
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.67 |
Daily Volume: | 0 |
Market Cap: | US$15.730M |
November 12, 2024 August 29, 2024 August 13, 2024 March 28, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load